Search results
Results from the WOW.Com Content Network
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made ...
Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst Skip to main content
Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (NYSE: DNA) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New ...
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $2.84, moving -0.35% from the previous trading session.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology .
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.78, marking a +0.72% move from the previous day.
[5] [31] [37] Complete Genomics is a US-based subsidiary of MGI, MGI was a subsidiary of BGI before it was spun out and listed on the Shanghai Stock Exchange in 2022. [38] In 2015, BGI signed a collaboration with the Zhongshan Hospital' Center for Clinical Precision Medicine in Shanghai, opened in May 2015 with a budget of ¥100 million. They ...
Can this struggling stock turn things around? For premium support please call: 800-290-4726 more ways to reach us